About Paratek Pharmaceuticals (NASDAQ:PRTK)
Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:PRTK
- CUSIP: 89354M10
- Web: www.paratekpharma.com
Capitalization:- Market Cap: $644.06 million
- Outstanding Shares: 27,761,000
Average Prices:- 50 Day Moving Avg: $25.31
- 200 Day Moving Avg: $22.89
- 52 Week Range: $9.80 - $29.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.32
- P/E Growth: -0.02
Sales & Book Value:- Annual Revenue: $7.56 million
- Price / Sales: 85.19
- Book Value: $4.11 per share
- Price / Book: 5.64
Profitability:- EBITDA: ($90,380,000.00)
- Return on Equity: -107.52%
- Return on Assets: -64.00%
Debt:- Debt-to-Equity Ratio: 0.43%
- Current Ratio: 11.88%
- Quick Ratio: 11.88%
Misc:- Average Volume: 639,723 shs.
- Beta: 0.8
- Short Ratio: 3.22
Frequently Asked Questions for Paratek Pharmaceuticals (NASDAQ:PRTK)
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.25. The company earned $7.51 million during the quarter, compared to the consensus estimate of $7.50 million. View Paratek Pharmaceuticals' Earnings History.
Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?
8 equities research analysts have issued 1 year price objectives for Paratek Pharmaceuticals' shares. Their predictions range from $23.00 to $56.00. On average, they expect Paratek Pharmaceuticals' stock price to reach $39.50 in the next year. View Analyst Ratings for Paratek Pharmaceuticals.
What are analysts saying about Paratek Pharmaceuticals stock?
Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (10/11/2017)
- 2. Cantor Fitzgerald analysts commented, "There has been a lot of interest this morning in headlines stating that PRTK is considering all of its strategic options including a sale of the company. We have always believed that PRTK is a very interesting asset in a consolidating space where many antibiotic companies have been taken out. Please see our previously published research on PRTK for more details on our thoughts here. With positive Phase 3 data, PRTK is at the inflection point where potential acquirors would take a look since the asset has been de-risked." (8/23/2017)
- 3. Robert W. Baird analysts commented, "Though sarecycline is not a key driver, it provides a potential source of non-dilutive financing and further validates Paratek's ability to develop a once daily, well tolerated, tetracycline-derived antibiotic. Looking ahead, we expect continued momentum with focus on key upcoming data readouts from two Phase 3 studies of omadacycline in 2Q17, supporting filing in 1H18, and we reiterate our Outperform rating." (3/27/2017)
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Acorda Therapeutics (ACOR), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK), Ascendis Pharma A/S (ASND), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), NeuroDerm (NDRM), REGENXBIO (RGNX), Xencor (XNCR), Epizyme (EPZM), Athenex (ATNX), Retrophin (RTRX), Amarin Corporation PLC (AMRN), Ignyta (RXDX), Reata Pharmaceuticals (RETA), Omeros Corporation (OMER) and Cytokinetics, Incorporated (CYTK).
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Michael F. Bigham CPA, Chairman of the Board, Chief Executive Officer
- Evan Loh M.D., President, Chief Operating Officer, Chief Medical Officer, Director
- Douglas W Pagan, Chief Financial Officer
- William M. Haskel, Senior Vice President, General Counsel, Corporate Secretary
- Regina D. Paglia, Senior Vice President - Human Resources
- Jeanne Jew, Senior Vice President - Business Development
- Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations
- Rajesh Padmanabhan, Vice President - Information Technology
- Stephen Villano M.D., Vice President - Clinical and Medical Affairs
- Adam Woodrow, Vice President and Chief Commercial Officer
How do I buy Paratek Pharmaceuticals stock?
Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $23.20.
MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.13) |
| Consensus Price Target: | $39.50 (70.26% upside) |
Consensus Price Target History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/17/2017 | Cantor Fitzgerald | Set Price Target | Buy | $50.00 | N/A |  |
| 8/24/2017 | Raymond James Financial, Inc. | Reiterated Rating | Strong-Buy | $36.00 | Medium | |
| 7/18/2017 | HC Wainwright | Boost Price Target | Positive -> Buy | $36.00 -> $43.00 | High | |
| 4/4/2017 | Guggenheim | Set Price Target | Buy | $38.00 | Medium | |
| 4/4/2017 | BTIG Research | Boost Price Target | Buy | $47.00 -> $56.00 | Medium | |
| 4/4/2017 | Robert W. Baird | Reiterated Rating | Outperform | $40.00 | Medium | |
| 4/3/2017 | Wedbush | Reiterated Rating | Outperform -> Outperform | $30.00 | High | |
| 11/3/2016 | Leerink Swann | Reiterated Rating | Buy | $23.00 | N/A | |
| 6/17/2016 | Ladenburg Thalmann Financial Services | Boost Price Target | Buy | $46.00 -> $52.00 | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)Earnings History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | Q2 2017 | ($0.89) | ($0.64) | $7.50 million | $7.51 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($1.20) | ($1.14) | | $0.02 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($1.33) | ($1.17) | | $0.03 million | View | Listen | |
| 11/2/2016 | | ($1.38) | ($1.04) | | | View | N/A | |
| 5/2/2016 | | ($1.25) | ($1.77) | | | View | N/A | |
| 2/23/2016 | Q4 | ($1.18) | ($1.20) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.91) | ($1.33) | | | View | Listen | |
| 8/5/2015 | Q215 | ($0.75) | ($0.94) | $3.62 billion | | View | N/A | |
| 4/2/2015 | Q1 | ($2.16) | ($0.74) | $0.13 million | $4.00 million | View | N/A | |
| 5/5/2014 | | ($0.18) | ($0.15) | | $0.42 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.21) | ($0.29) | $0.50 million | $0.32 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.42) | ($0.56) | | | View | N/A | |
| 11/12/2012 | Q312 | $0.06 | $0.25 | $8.37 million | $10.44 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)2017 EPS Consensus Estimate: ($3.64)
2018 EPS Consensus Estimate: ($2.96)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.15) | ($1.15) | ($1.15) |
| Q2 2017 | 1 | ($0.79) | ($0.79) | ($0.79) |
| Q3 2017 | 2 | ($0.92) | ($0.87) | ($0.90) |
| Q4 2017 | 2 | ($0.94) | ($0.67) | ($0.81) |
| Q1 2018 | 1 | ($0.86) | ($0.86) | ($0.86) |
| Q2 2018 | 1 | ($0.89) | ($0.89) | ($0.89) |
| Q3 2018 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q4 2018 | 1 | ($0.73) | ($0.73) | ($0.73) |
(Data provided by Zacks Investment Research)
Dividend History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/14/2014 | special | $1.33 | | 6/4/2014 | 5/26/2014 | 6/3/2014 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Paratek Pharmaceuticals (NASDAQ:PRTK)Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 82.37%
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Adam Woodrow | VP | Sell | 3,800 | $23.58 | $89,604.00 | |
| 7/5/2017 | Douglas W Pagan | CFO | Sell | 4,139 | $23.58 | $97,597.62 | |
| 7/5/2017 | Evan Loh | COO | Sell | 4,351 | $23.58 | $102,596.58 | |
| 7/5/2017 | Michael Bigham | Chairman | Sell | 5,075 | $23.58 | $119,668.50 | |
| 6/19/2017 | Douglas W Pagan | CFO | Sell | 4,595 | $25.00 | $114,875.00 | |
| 2/6/2017 | Douglas W Pagan | CFO | Sell | 3,405 | $15.09 | $51,381.45 | |
| 2/6/2017 | Evan Loh | COO | Sell | 3,106 | $15.09 | $46,869.54 | |
| 2/6/2017 | Michael Bigham | Chairman | Sell | 5,000 | $15.09 | $75,450.00 | |
| 6/27/2016 | Fund Iv L.P. Omega | Major Shareholder | Buy | 461,538 | $13.00 | $5,999,994.00 | |
| 6/23/2016 | Michael Bigham | CEO | Buy | 20,000 | $13.45 | $269,000.00 | |
| 12/11/2015 | Evan Loh | CMO | Buy | 2,300 | $16.87 | $38,801.00 | |
| 5/29/2015 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 20,580 | $30.75 | $632,835.00 | |
| 12/13/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 1,470 | $3.54 | $5,203.80 | |
| 12/11/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,490 | $3.55 | $37,239.50 | |
| 12/6/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 8,710 | $3.54 | $30,833.40 | |
| 12/4/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,120 | $3.50 | $24,920.00 | |
| 11/20/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,040 | $3.57 | $35,842.80 | |
| 11/12/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,190 | $3.53 | $25,380.70 | |
| 11/7/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 4,960 | $3.61 | $17,905.60 | |
| 10/30/2013 | Roumell Asset Management, Llc | Major Shareholder | Sell | 7,020 | $3.69 | $25,903.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Paratek Pharmaceuticals (NASDAQ:PRTK)
Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
| Source: |
|
| Date | Headline |
|---|
 | Oversold Conditions For Paratek Pharmaceuticals (PRTK)
www.thestreet.com - October 19 at 7:46 AM |
 | Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : October 18, 2017
finance.yahoo.com - October 19 at 7:46 AM |
| Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PRTK-US : October 17, 2017
finance.yahoo.com - October 17 at 4:15 PM |
 | Paratek Pharmaceuticals, Inc. (PRTK) Given a $50.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - October 17 at 3:32 PM |
| Zacks Investment Research Lowers Paratek Pharmaceuticals, Inc. (PRTK) to Sell
www.americanbankingnews.com - October 11 at 10:20 AM |
| Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals and 22nd Century Group
finance.yahoo.com - October 10 at 2:38 AM |
| Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
finance.yahoo.com - October 8 at 5:10 AM |
| Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
finance.yahoo.com - October 8 at 5:10 AM |
| Paratek Pharma shares surge 6% on late-stage results for antibiotic
finance.yahoo.com - October 8 at 5:10 AM |
 | Paratek Pharmaceuticals (PRTK) Says Phase 3 Optic Study Microbiology Data Shows Omadacycline has Potent In vitro ... - StreetInsider.com
www.streetinsider.com - October 7 at 7:34 AM |
 | Paratek Pharma shares surge 6% on late-stage results for antibiotic - MarketWatch
www.marketwatch.com - October 7 at 7:34 AM |
 | Major Biotech, Pharma and FDA Catalysts Coming in October
247wallst.com - September 30 at 9:53 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 30 at 7:08 AM |
 | Paratek Pharmaceuticals (PRTK) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 4:23 PM |
 | Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017 - GlobeNewswire (press release)
globenewswire.com - September 26 at 7:05 PM |
| Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
finance.yahoo.com - September 25 at 12:29 PM |
| Head-To-Head Contrast: Paratek Pharmaceuticals (PRTK) & Its Peers
www.americanbankingnews.com - September 24 at 2:18 AM |
| Contrasting Auris Medical Holding AG (EARS) & Paratek Pharmaceuticals (PRTK)
www.americanbankingnews.com - September 23 at 8:30 PM |
| Paratek's omadacycline granted additional QIDP status in US - Seeking Alpha
seekingalpha.com - September 23 at 12:38 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - September 22 at 3:50 PM |
| Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections
finance.yahoo.com - September 22 at 2:24 PM |
| Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017
finance.yahoo.com - September 20 at 7:57 AM |
| Brokerages Expect Paratek Pharmaceuticals, Inc. (PRTK) Will Announce Earnings of -$0.93 Per Share
www.americanbankingnews.com - September 17 at 2:28 AM |
| Paratek Pharmaceuticals (PRTK) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 8:00 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 5 at 6:50 AM |
| Paratek Announces Inducement Grants under NASDAQ Listing Rule ... - GlobeNewswire (press release)
globenewswire.com - September 2 at 7:44 AM |
| Here's Why Paratek Pharmaceuticals Soared as Much as 37% Today
finance.yahoo.com - August 24 at 11:23 AM |
| Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.
finance.yahoo.com - August 24 at 11:23 AM |
| Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : August 24, 2017
finance.yahoo.com - August 24 at 11:23 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%
finance.yahoo.com - August 24 at 11:23 AM |
| Paratek Pharmaceuticals' (PRTK) Strong-Buy Rating Reiterated at Raymond James Financial, Inc.
www.americanbankingnews.com - August 24 at 10:34 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - August 23 at 10:54 AM |
| Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor ... - GlobeNewswire (press release)
globenewswire.com - August 23 at 1:59 AM |
| Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
finance.yahoo.com - August 22 at 3:55 PM |
| Paratek Pharmaceuticals (PRTK) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 17 at 7:03 AM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 11 at 3:24 PM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Earns "Overweight" Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 10 at 12:46 PM |
| Brokers Offer Predictions for Paratek Pharmaceuticals, Inc.'s FY2017 Earnings (NASDAQ:PRTK)
www.americanbankingnews.com - August 10 at 10:42 AM |
| Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : August 9, 2017
finance.yahoo.com - August 10 at 7:02 AM |
| Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:33 AM |
| Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 6:33 AM |
| Paratek Pharmaceuticals (PRTK) Gains Tied to Amendment to Change of Control Policy - StreetInsider.com
www.streetinsider.com - August 8 at 6:22 AM |
| Paratek Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($0.87) Per Share, Wedbush Forecasts (NASDAQ:PRTK)
www.americanbankingnews.com - August 7 at 7:34 AM |
| FY2017 Earnings Estimate for Paratek Pharmaceuticals, Inc. (PRTK) Issued By Gabelli
www.americanbankingnews.com - August 7 at 7:06 AM |
| Brokers Set Expectations for Paratek Pharmaceuticals, Inc.'s Q3 2017 Earnings (NASDAQ:PRTK)
www.americanbankingnews.com - August 4 at 7:22 AM |
| Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : August 4, 2017
finance.yahoo.com - August 4 at 7:13 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Announces Quarterly Earnings Results, Beats Estimates By $0.25 EPS
www.americanbankingnews.com - August 3 at 2:52 PM |
| Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - August 3 at 7:06 AM |
| Edited Transcript of PRTK earnings conference call or presentation 2-Aug-17 12:30pm GMT
finance.yahoo.com - August 3 at 7:06 AM |
| Paratek reports 2Q loss
finance.yahoo.com - August 3 at 7:06 AM |
Paratek Pharmaceuticals (PRTK) Chart for Friday, October, 20, 2017
